関: 4-aminosalicylic acid、calcium p-aminosalicylate、calcium para-aminosalicylate、p-aminosalicylate、para-aminosalicylic acid、PAS

WordNet

send a message from one computer to another to check whether it is reachable and active; "ping your machine in the office"
a sharp high-pitched resonant sound (as of a sonar echo or a bullet striking metal)
contact, usually in order to remind of something; "Ill ping my accountant--April 15 is nearing"
hit with a pinging noise; "The bugs pinged the lamp shade"
make a short high-pitched sound; "the bullet pinged when they struck the car"
street name for lysergic acid diethylamide (同)back breaker, battery-acid, dose, dot, Elvis, loony toons, Lucy in the sky with diamonds, pane, superman, window pane, Zen
any of various water-soluble compounds having a sour taste and capable of turning litmus red and reacting with a base to form a salt
having the characteristics of an acid; "an acid reaction"
the 16th letter of the Roman alphabet (同)p

PrepTutorEJDIC

(小銃弾などの)ピュー(ブーン)という音 / ピュー(ブーン)と音がする
酸性の / 酸味のある,すっぱい(sour) / (言葉・態度などが)厳しい,しんらつな / 酸 / すっぱいもの / 《俗》=LSD
parking
phosphorusの化学記号

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/10/23 16:36:24」(JST)

wiki en

4-aminosalicylic acid, commonly known as PAS, is an antibiotic used to treat tuberculosis.^[1] This organic compound has also been use since the 1940s for the treatment of inflammatory bowel diseases (IBDs), where it has shown greater potency in ulcerative colitis and Crohn's disease.^[2] It is thought to act via NF-κB (nuclear factor-kappa B) inhibition and free radical scavenging. 5-Aminosalicylic acid, sold under the name mesalazine, is a closely related compound that also has medical uses.

Medical uses

The main use for 4-aminosalicyclic acid is for the treatment of tuberculosis infections.

Tuberculosis

Aminosalicylic acid was introduced to clinical use in 1948. It was the second antibiotic found to be effective in the treatment of tuberculosis, after streptomycin. PAS formed part of the standard treatment for tuberculosis prior to the introduction of rifampicin and pyrazinamide.^[3]

Its potency is less than that of the current five first-line drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin) for treating tuberculosis and its cost is higher, but it is still useful in the treatment of multidrug-resistant tuberculosis.^[1] PAS is always used in combination with other anti-TB drugs.

The dose when treating tuberculosis is 150 mg/kg/day divided into two to four daily doses; the usual adult dose is therefore approximately 2 to 4 grams four times a day. It is sold in the US as "Paser" by Jacobus Pharmaceutical, which comes in the form of 4 g packets of delayed-release granules. The drug should be taken with acid food or drink (orange, apple or tomato juice).^[4] PAS was once available in a combination formula with isoniazid called Pasinah^[5] or Pycamisan 33.^[6]

The European Medicines Agency (EMA) has recommended granting a marketing authorization for PAS in multidrug-resistant tuberculosis in adults and children when other treatments cannot "be devised for reasons of resistance or tolerability."^[7]

Inflammatory bowel disease

PAS has also been used in the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease),^[2] but has been superseded by other drugs such as sulfasalazine and mesalazine.

Others

PAS has been investigated for the use in manganese chelation therapy, and a 17-year follow-up study shows that it might be superior to other chelation protocols such as EDTA.^[8]

Pharmacology

With heat, aminosalicylic acid is decarboxylated to produce CO₂ and 3-aminophenol.^[9]

The U.S. FDA assigned PAS to pregnancy category C, indicating that it is not known whether it will harm an unborn baby.

Side effects

Gastrointestinal side-effects (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem.^[10] It is also a cause of drug-induced hepatitis. Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis.^[11] Thyroid goitre is also a side-effect because aminosalicylic acid inhibits the synthesis of thyroid hormones.^[12]

Drug interactions include elevated phenytoin levels. When taken with rifampicin, the levels of rifampicin in the blood fall by about half.^[13]

History

PAS was discovered by the Swedish chemist Jörgen Lehmann upon the report that the tuberculosis bacterium avidly metabolized salicylic acid. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery.^[14] The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In the 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone.^[1]

Synthesis

PAS is manufactured by the carboxylation of 3-aminophenol.^[15]

Other names

Like many commercially significant compounds, PAS has many names including para-aminosalicylic acid, p-aminosalicylic acid, 4-ASA, and simply P.

Mode of action

PAS has been shown to be a pro-drug and it is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity.^[16]

External links

Drugs.com
RxList

References

^ ^a ^b ^c Fox, W.; Ellard, G. A.; Mitchison, D. A. (1999). "Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications". The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 3 (10 Suppl 2): S231–S279. PMID 10529902. edit
^ ^a ^b Daniel F, Seksik P, Cacheux W, Jian R, Marteau P (2004). "Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis". Inflamm Bowel Dis 10 (3): 258–260. doi:10.1097/00054725-200405000-00013. PMID 15290921.
^ Mitchison DA (2000). "Role of individual drugs in the chemotherapy of tuberculosis Role of individual drugs in the chemotherapy of tuberculosis". Int J Tuberc Lung Dis 4 (9): 796–806. PMID 10985648.
^ "Paser". RxList. Archived from the original on 25 October 2008. Retrieved 2008-10-10.
^ Smith NP, Ryan TJ, Sanderson KV, Sarkany I (1976). "Lichen scrofulosorum: A report of four cases". Br J Dermatol 94 (3): 319–325. doi:10.1111/j.1365-2133.1976.tb04391.x. PMID 1252363.
^ Black JM; Sutherland, IB (1961). "Two incidents of tuberculous infection by milk from attested herds". Br Med J 1 (5241): 1732–1735. doi:10.1136/bmj.1.5241.1732. PMC 1954350. PMID 20789163.
^ Drug Discovery & Development. EMA Recommends Two New Tuberculosis Treatments. November 22, 2013.
^ Jiang, Y. M.; Mo, X. A.; Du, F. Q.; Fu, X.; Zhu, X. Y.; Gao, H. Y.; Xie, J. L.; Liao, F. L.; Pira, E.; Zheng, W. (2006). "Effective Treatment of Manganese-Induced Occupational Parkinsonism with p-Aminosalicylic Acid: A Case of 17-Year Follow-Up Study". Journal of Occupational and Environmental Medicine 48 (6): 644–649. doi:10.1097/01.jom.0000204114.01893.3e. PMID 16766929. edit
^ Vetuschi, C.; Ragno, G.; Mazzeo, P. (1988). "Determination of p-aminosalicylic acid and m-aminophenol by derivative UV-spectrophotometry". Journal of pharmaceutical and biomedical analysis 6 (4): 383–391. doi:10.1016/0731-7085(88)80003-7. PMID 16867404. edit
^ Das, K. M.; Eastwood, M. A.; McManus, J. P. A.; Sircus, W. (1973). "Adverse Reactions during Salicylazosulfapyridine Therapy and the Relation with Drug Metabolism and Acetylator Phenotype". New England Journal of Medicine 289 (10): 491–495. doi:10.1056/NEJM197309062891001. PMID 4146729. edit
^ Szeinberg, A.; Sheba, C.; Hirshorn, N.; Bodonyi, E. (1957). "Studies on erthrocytes in cases with past history of favism and drug-induced acute hemolytic anemia". Blood 12 (7): 603–613. PMID 13436516. edit
^ MacGregor, A. G.; Somner, A. R. (1954). "The anti-thyroid action of para-aminosalicylic acid". Lancet 267 (6845): 931–936. PMID 13213079. edit
^ Boman G (1974). "Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid". European journal of clinical pharmacology 7 (3): 217–25. doi:10.1007/BF00560384. PMID 4854257.
^ Lehmann, J. (1946). "Para-aminosalicylic acid in the treatment of tuberculosis". Lancet 1 (6384): 15. doi:10.1016/s0140-6736(46)91185-3. PMID 21008766. edit
^ Mitchell, S. C.; Waring, R. H. (2000). "Aminophenols". "Ullmann's Encyclopedia of Industrial Chemistry". doi:10.1002/14356007.a02_099. ISBN 3527306730. edit
^ Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 288(32):23447-56. http://www.jbc.org/content/288/32/23447.long

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 炎症性腸疾患治療におけるスルファサラジンおよび5-アミノサリチル酸 sulfasalazine and 5 aminosalicylates in the treatment of inflammatory bowel disease
2. セカンドラインの抗結核療法 second line antituberculous therapy
3. 重症の潰瘍性大腸炎のマネージメント management of severe ulcerative colitis
4. 炎症性腸疾患の肺合併症 pulmonary complications of inflammatory bowel disease
5. 空置性大腸炎 diversion colitis

English Journal

Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations.

Goyanes A1, Hatton GB1, Merchant HA2, Basit AW3.
International journal of pharmaceutics.Int J Pharm.2015 Apr 30;484(1-2):103-8. doi: 10.1016/j.ijpharm.2015.02.051. Epub 2015 Feb 23.
The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial form
PMID 25721685

Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis.

Hoy SM1.
Drugs.Drugs.2015 Apr 29. [Epub ahead of print]
Budesonide MMX® (Cortiment®; Uceris®) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX®) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients wi
PMID 25920500

Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro.

Broekman MM1, Roelofs HM, Wong DR, Kerstholt M, Leijten A, Hoentjen F, Peters WH, Wanten GJ, de Jong DJ.
Cell biology and toxicology.Cell Biol Toxicol.2015 Apr 28. [Epub ahead of print]
INTRODUCTION: The use of thiopurines is frequently accompanied by hepatotoxicity. Studies on hepatocyte cultures showed a time- and dose-dependent increase of thiopurine toxicity. 5-Aminosalicylic acid (5-ASA) and allopurinol can influence thiopurine metabolism; however, it is unknown whether this a
PMID 25916701

Japanese Journal

Production of p-Aminosalicylic Acid through Enzymatic Kolbe-Schmitt Reaction Catalyzed by Reversible Salicylic Acid Decarboxylase

KIRIMURA Kohtaro,YANASO Satomi,KOSAKA Sachiyo,KOYAMA Keiko,HATTORI Takasumi,ISHII Yoshitaka
Chemistry letters 40(2), 206-208, 2011-02-05
NAID 10027815087

Mycobacterium szulgai 肺感染症の1例

池上達義,渡邊茂樹,杉田孝和,堀川禎夫,鈴木雄二郎,西山秀樹,前川暢夫
結核 77(5), 427-431, 2002-05-15
… An acid-fast stain of bronchial washing fluid was positive, and antimycobacterial chemotherapy with isoniazid (400 mg/day), rifampin (450 mg/day), and ethambutol (750 mg/day) was initiated on presumptive diagnosis of the case as tuberculosis. …
NAID 10008879622

Related Pictures

★リンクテーブル★

リンク元	「パラアミノサリチル酸」「PAS」「calcium p-aminosalicylate」「p-アミノサリチル酸」「4-aminosalicylic acid」
関連記事	「P」「ps」「p」

「パラアミノサリチル酸」

4-Aminosalicylic acid
Systematic (IUPAC) name
	4-amino-2-hydroxy-benzoic acid
Clinical data
Trade names	Paser
Pregnancy cat.	C;
Legal status	UK: Rx-only;
Routes	Oral
Pharmacokinetic data
Protein binding	50–60%
Metabolism	Hepatic
Excretion	Renal
Identifiers
CAS number	65-49-6
ATC code	J04AA01
PubChem	CID 4649
DrugBank	DB00233
ChemSpider	4488
UNII	5B2658E0N2
KEGG	D00162
ChEBI	CHEBI:27565
ChEMBL	CHEMBL1169
NIAID ChemDB	020064
Chemical data
Formula	C7H7NO3
Mol. mass	153.135 g/mol
	SMILES O=C(O)c1ccc(cc1O)N;
	InChI InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11) ; Key:WUBBRNOQWQTFEX-UHFFFAOYSA-N ;
Physical data
Melt. point	150.5 °C (303 °F)
(what is this?) (verify)